Immune Thrombocytopenia Refractory to First-Line Therapy: Choosing the Next Step
A 34-year-old woman is diagnosed with primary immune thrombocytopenia (ITP) after an isolated platelet count of 18 × 10^9/L on two occasions; she has petechiae on her shins but no mucosal bleeding, no splenomegaly, and no other cytopenias. HIV, hepatitis B and C serology, and H. pylori testing are negative. She is started on prednisone 1 mg/kg/day. After 3 weeks her platelet count is 24 × 10^9/L, and she reports insomnia, weight gain, and a fasting glucose of 168 mg/dL. She works as a middle-school teacher and is anxious about missing work. She asks whether she can 'just stop the steroids and wait it out.'
1. How should you frame the immediate decision about continuing, tapering, or changing therapy, and what does the evidence say about the natural history of untreated ITP in an adult?
Read the worked answer
Framing the decision. She has not achieved a response (platelets <30 × 10^9/L with no doubling from baseline) after 3 weeks of adequate-dose steroids, and she is developing steroid toxicity (hyperglycemia, insomnia). Continuing full-dose prednisone beyond ~2–3 weeks adds toxicity without proven benefit in a non-responder.
Natural history. Adult ITP is usually chronic; spontaneous durable remission is uncommon (roughly 20–30% over years), so 'waiting it out' is not a reliable plan when she is symptomatic and at risk of bleeding. This is not a pediatric-style watch-and-wait scenario.
Practical plan. Taper steroids rather than stop abruptly (adrenal suppression after 3 weeks), and move to a second-line agent. Reasonable options include a thrombopoietin receptor agonist (TPO-RA) or rituximab; splenectomy is deferred. Her occupational bleeding risk (teacher, low-trauma) and glucose intolerance favor avoiding prolonged steroids.
Communication. Explain that the goal is a platelet count that prevents bleeding, not a 'normal' number, and that treatment choice balances speed, durability, and her work schedule - this is a shared decision, not a single correct drug.
2. If she asks about starting a thrombopoietin receptor agonist, what monitoring and counseling points matter, and how do you weigh it against rituximab for her?
Read the worked answer
TPO-RA counseling.
- Response takes 1–2 weeks; requires weekly CBC during dose titration, then periodic monitoring.
- Risks: thrombocytosis, headache, and (for romiplostim/eltrombopag) hepatotoxicity - check LFTs. There is a boxed warning for marrow reticulin fibrosis and rebound thrombocytopenia on discontinuation; taper rather than stop abruptly.
- Eltrombopag chelates cations - separate from calcium/iron/magnesium-containing foods and antacids by ~4 hours; romiplostim is weekly subcutaneous injection.
- Requires ongoing adherence; platelets often fall when stopped.
Rituximab comparison. Rituximab offers a chance of durable off-treatment remission (~20–25% at 5 years) but onset is slower (4–8 weeks) and carries infusion reactions, rare PML, and hepatitis B reactivation risk (she is HBV-negative, so lower concern).
Weighing for her. A TPO-RA gives faster, more reliable platelet support and fits a teacher's need to stay at work; rituximab appeals if she wants a chance to be off chronic therapy. Either is defensible; document the discussion.